Prostate in flammation and prostate cancer

Management of Prostate Cancer: Third Edition

Volumn , Issue , 2013, Pages 103-115

  Nelson, William G ^a   Sfanos, Karen S ^b   DeMarzo, Angelo M ^b   Yegnasubramanian, Srinivasan ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017160117     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-259-9_6     Document Type: Chapter

References (112)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-81.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. In fl ammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-69.
3. Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis: management strategies. Drugs. 2009;69:71-84.
4. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009;150:3991-4002.
5. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-in fl ammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol. 2009;9:419-26.
6. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27-33.
7. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60:78-83.
8. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One. 2010;5:e8736.
9. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The in fl uence of fi nasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-24.
10. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative in fl ammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985-92.
11. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, et al. A working group classi fi cation of focal prostate atrophy lesions. Am J Surg Pathol. 2006;30:1281-91.
12. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostatein fi ltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254-61.
13. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-in fi ltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009;69:1694-703.
14. Elkord E, Rowbottom AW, Kynaston H, Williams PE. Correlation between CD8+ T cells speci fi c for prostate-speci fi c antigen and level of disease in patients with prostate cancer. Clin Immunol. 2006;120:91-8.
15. Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA, et al. Identi fi cation of HLA-DRB11501-restricted T-cell epitopes from prostate-speci fi c antigen. Clin Cancer Res. 2005;11: 2853-61.
16. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, et al. Prostate stem cell antigen: identi fi cation of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer. 2002;102:390-7.
17. Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB. Acute in fl ammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci USA. 2009;106:3443-8.
18. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative in fl ammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000;56:828-32.
19. Wang W, Bergh A, Damber JE. Morphological transition of proliferative in fl ammatory atrophy to highgrade intraepithelial neoplasia and cancer in human prostate. Prostate. 2009;69:1378-86.
20. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol. 2001;158:1767-73.
21. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006;66: 10683-90.
22. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21:1156-67.
23. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative in fl ammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol. 2003;163:923-33.
24. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and in fl ammation: emerging insights. Carcinogenesis. 2005;26:1170-81.
25. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One. 2010;5:e9427.
26. Elkahwaji JE, Hauke RJ, Brawner CM. Chronic bacterial in fl ammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer. 2009;101: 1740-8.
27. Elkahwaji JE, Zhong W, Hopkins WJ, Bushman W. Chronic bacterial infection and in fl ammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate. 2007;67:14-21.
28. Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, et al. Sexually transmitted infections and prostatic in fl ammation/cell damage as measured by serum prostate speci fi c antigen concentration. J Urol. 2006;175:1937-42.
29. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-speci fi c antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411-6.
30. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13:72-9.
31. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 2009;384:260-5.
32. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, et al. Identi fi cation of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006;2:e25.
33. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA. 2007;104(5): 1655-60.
34. Rusmevichientong A, Chow SA. Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. Immunol Res. 2010;48(1-3):27-39.
35. Alexeyev O, Bergh J, Marklund I, Thellenberg- Karlsson C, Wiklund F, Gronberg H, et al. Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control. 2006;17: 1127-33.
36. Alexeyev OA, Marklund I, Shannon B, Golovleva I, Olsson J, Andersson C, et al. Direct visualization of Propionibacterium acnes in prostate tissue by multicolor fl uorescent in situ hybridization assay. J Clin Microbiol. 2007;45:3721-8.
37. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with in fl ammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol. 2005;173:1969-74.
38. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, De Matteo E, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res. 2002;62:4876-8.
39. Okudaira H. Pathogenesis of allergic diseases: interactions between pollutants and pollens really important? Allerg Immunol (Paris). 2000;32:94-6.
40. Yasui Y, Potter JD, Stanford JL, Rossing MA, Winget MD, Bronner M, et al. Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiol Biomarkers Prev. 2001; 10:9-16.
41. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-22.
42. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007;92:2519-25.
43. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439-43.
44. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42: 668-75.
45. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-8.
46. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol. 1988;140:1049-53.
47. Stoker TE, Robinette CL, Britt BH, Laws SC, Cooper RL. Prepubertal exposure to compounds that increase prolactin secretion in the male rat: effects on the adult prostate. Biol Reprod. 1999;61:1636-43.
48. Stoker TE, Robinette CL, Cooper RL. Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of in fl ammation in the ventral and lateral lobes. Reprod Toxicol. 1999;13:463-72.
49. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol. 2007;23(3):374-82.
50. Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci. 2006;1089:168-76.
51. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561-70.
52. Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology. 2001;57: 31-8.
53. Knize MG, Salmon CP, Mehta SS, Felton JS. Analysis of cooked muscle meats for heterocyclic aromatic amine carcinogens. Mutat Res. 1997;376: 129-34.
54. Lijinsky W, Shubik P. Benzo(a)pyrene and other polynuclear hydrocarbons in charcoal-broiled meat. Science. 1964;145:53-5.
55. Shirai T, Cui L, Takahashi S, Futakuchi M, Asamoto M, Kato K, et al. Carcinogenicity of 2-amino-1- methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett. 1999;143:217-21.
56. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6- phenylimidazo[4,5- b]pyridine (PhIP) derived from cooked foods. Cancer Res. 1997;57:195-8.
57. Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007;67:1378-84.
58. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. In fl ammation and atrophy precede prostatic neoplasia in a PhIPinduced rat model. Neoplasia. 2006;8:708-15.
59. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol. 1992;43:557-64.
60. Hsu A, Bruno RS, Lohr CV, Taylor AW, Dashwood RH, Bray TM, et al. Dietary soy and tea mitigate chronic in fl ammation and prostate cancer via NFkappaB pathway in the Noble rat model. J Nutr Biochem. 2011;22(5):502-10.
61. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66:1234-40.
62. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995;92:5258-65.
63. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res. 2001;477:7-21.
64. Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, et al. Nitric oxide is a key component in in fl ammation-accelerated tumorigenesis. Cancer Res. 2008;68:7130-6.
65. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90:1219-24.
66. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001;166:2034-8.
67. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst. 2004;96:696-703.
68. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301: 39-51.
69. Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol. 2003;170:2471-4.
70. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009;27:3577-83.
71. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010;3:604-10.
72. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59:1225-30.
73. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst. 2000;92:61-8.
74. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-speci fi c antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12:4018-26.
75. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs. 2006;15:1191-200.
76. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis. 2007;28:1946-53.
77. Brooks JD, Paton V. Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. Prostate Cancer Prostatic Dis. 1999;2:S8.
78. Brooks JD, Paton VG, Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev. 2001;10:949-54.
79. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Shari fi R, Ghosh L, van Breemen R, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93:1872-9.
80. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30:181-4.
81. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32:321-5.
82. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell. 1993;72:753-65.
83. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, et al. Interferon action and apoptosis are defective in mice devoid of 2' ,5 '-oligoadenylatedependent RNase L. EMBO J. 1997;16:6355-63.
84. Peiser L, Gough PJ, Kodama T, Gordon S. Macrophage class A scavenger receptor-mediated phagocytosis of Escherichia coli: role of cell heterogeneity, microbial strain, and culture conditions in vitro. Infect Immun. 2000;68:1953-63.
85. Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med. 2000;191:147-56.
86. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002;32(4):581-3.
87. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B, et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet. 2003;72:208-12.
88. Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bona D, et al. Polymorphisms of pro-in fl ammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009;58:1919-33.
89. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of tolllike receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 2004;64:2918-22.
90. Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer. 2008;123:2644-50.
91. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA. 1994;91:11733-7.
92. Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate. 2001;49:30-7.
93. Ritchie KJ, Walsh S, Sansom OJ, Henderson CJ, Wolf CR. Markedly enhanced colon tumorigenesis in ApcMin mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci USA. 2009;106(49): 20859-64.
94. Suzuki H, Toyota M, Kondo Y, Shinomura Y. In fl ammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. Methods Mol Biol. 2009;512:55-69.
95. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, et al. Methylation of polycomb target genes in intestinal cancer is mediated by in fl ammation. Cancer Res. 2008;68:10280-9.
96. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, et al. Association of aspirin and nonaspirin nonsteroidal anti-in fl ammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99:881-9.
97. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-in fl ammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975-80.
98. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99:608-15.
99. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, et al. Nonsteroidal antiin fl ammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev. 2005;14:390-6.
100. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, et al. Cyclooxygenase-2 is up-regulated in proliferative in fl ammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001;61:8617-23.
101. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975-86.
102. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-in fl ammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004;90:93-9.
103. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-in fl ammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev. 2006;15:158-64.
104. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1108-11.
105. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti- in fl ammatory drugs (NSAIDs): results of a case-control study. Oncol Rep. 2000;7:169-70.
106. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiin fl ammatory drug use and risk of prostate cancer. Int J Cancer. 2003;106:409-15.
107. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-speci fi c biomarkers. J Clin Oncol. 2009;27:4986-93.
108. Jain MK, Ridker PM. Anti-in fl ammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-87.
109. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98:1819-25.
110. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:2218-25.
111. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2007;16: 2213-7.
112. Krieger JN, Nyberg L, Nickel JC. NIH consensus de fi nition and classi fi cation of prostatitis. JAMA. 1999;282:236-7.